What is CRBU's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.05B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for CRBU?

P/E (TTM) is n/a and 52-week range is $0.44 to $3.54 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s CRBU figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for CRBU?

The company profile lists revenue (TTM) near $10M, net income (TTM) near $-10.16B, EPS (TTM) near $-1.08 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Caribou Biosciences Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Berkeley, California, US, 99.2M shares outstanding, ISIN US1420381089 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Caribou Biosciences Inc

$CRBU

Health Care · Biotechnology

IR Run Scenarios

$0.46

-4.36%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. The company is headquartered in Berkeley, California and currently employs 97 full-time employees. The company went IPO on 2021-07-23. The Company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform to offer broad access and rapid availability of treatments for patients with hematologic malignancies and autoimmune diseases. Its genome-editing platform, including its novel chRDNA technology, enables more precise genome editing of allogeneic cell therapies. The company is advancing its pipeline of allogeneic CAR-T cell therapies with clinical development programs targeting the treatment of hematologic malignancies and autoimmune diseases.

Employees

Website

www.cariboubio.com/

IPO

2021-07-23

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)